ADHD Medication in the UK: Complete Guide to Elvanse, Concerta & More (2026)

ADHD Medication in the UK: Complete Guide to Elvanse, Concerta & More (2026)

Finding the right ADHD medication is one of the most important decisions in your treatment journey. In the UK, there are four main medication classes approved for ADHD, each with different mechanisms, side effect profiles, and suitability for different patients. This guide covers everything you need to know about UK-approved medications, how titration works, and what to expect during monitoring.

Disclaimer: This is educational information, not medical advice. Always consult your prescribing clinician before making any changes to ADHD medication.

UK-Approved ADHD Medications: Overview

Methylphenidate (Concerta XL, Ritalin, Equasym XL)

Methylphenidate is the most commonly prescribed ADHD medication in the UK. It works by increasing dopamine and noradrenaline in the brain, improving focus, impulse control, and executive function.

• Concerta XL: Extended-release formulation with 8-12 hour duration. Typical starting dose is 18mg daily.
• Ritalin: Immediate-release, takes effect within 30 minutes. Often used for flexible dosing or to supplement long-acting medications.
• Equasym XL: Alternative extended-release option with similar onset and duration to Concerta.

Common side effects: Reduced appetite, insomnia, increased heart rate, nervousness, headache. Most side effects diminish over 2-4 weeks as your body adjusts.

Lisdexamfetamine (Elvanse)

Elvanse is a prodrug that requires liver metabolism to become active. This makes it safer for misuse potential compared to other stimulants, as it cannot be snorted or injected effectively. It typically has a smoother onset and longer duration than methylphenidate.

• Onset: 60-90 minutes (slower than methylphenidate, which reduces "rush" sensation)
• Duration: 10-13 hours
• Typical starting dose: 30mg daily
• Dosing range: 30-70mg daily

Why some prefer Elvanse: Longer duration means single daily dose; smoother onset with less "peak and crash"; lower misuse potential.

Atomoxetine (Strattera)

Atomoxetine is a non-stimulant that works as a noradrenaline reuptake inhibitor. It's useful if you have cardiovascular concerns, anxiety, or poor tolerance of stimulants.

• Onset: 2-4 weeks for full effect (takes longer than stimulants)
• Duration: 24 hours
• Typical starting dose: 40mg daily
• Key advantage: No abuse potential, no controlled drug restrictions
• Disadvantage: Slower onset; some report less dramatic improvement than stimulants

Guanfacine (Intuniv)

Guanfacine is an alpha-2A receptor agonist, typically used in combination with stimulants or as monotherapy when stimulants are unsuitable. It's particularly effective for impulse control and hyperactivity.

• Onset: 1-3 weeks
• Duration: 24 hours
• Typical starting dose: 1mg daily
• Effective for: Hyperactivity-impulsivity, anger outbursts, aggression

How Titration Works

Titration is the gradual process of finding your optimal dose. Your clinician will start with a low dose and slowly increase it while monitoring side effects and effectiveness.

• Stimulants (methylphenidate, Elvanse): Usually titrated weekly or every 2 weeks. Typical adjustment: +10mg (methylphenidate) or +10mg (Elvanse).
• Non-stimulants (atomoxetine, guanfacine): Slower titration over 3-4 weeks to minimize side effects.
• Target: Effective dose that improves symptoms with tolerable side effects.
• Maximum doses: Methylphenidate 90mg/day, Elvanse 70mg/day, Atomoxetine 100mg/day, Guanfacine 4mg/day.

Shared Care Agreements

In the UK, many patients receive ADHD medications through shared care agreements between specialist NHS services and their GP. This means:

• Specialist clinic performs initial diagnosis and titration
• GP takes over repeat prescribing once stable
• Regular monitoring blood pressure, heart rate, height, weight (for children/young people)
• Annual review with GP or specialist

NICE NG87 Monitoring Requirements

According to NICE NG87 guidelines, the following must be monitored:

• Before starting: Blood pressure, heart rate, weight, height, psychiatric history
• During titration: Weekly or fortnightly check-ins (in person or telephone)
• Once stable: Annual review including blood pressure and weight
• Blood tests: Not routinely required for stimulants, but baseline ECG if cardiovascular risk

Common Side Effects & How to Manage Them

Testing Before Starting Medication

Before you begin any ADHD medication, take our comprehensive assessments to better understand your symptoms and get an objective baseline:

• ADHD Screener — Identify core ADHD symptoms across inattention, hyperactivity, and impulsivity
• Neurodivergence Profile — Understand your full neurodivergent profile, including autism and ADHD traits

Key Takeaways

• Four main medication classes: methylphenidate, Elvanse, atomoxetine, and guanfacine
• Stimulants work faster but have higher abuse potential; non-stimulants are safer for certain patients
• Titration is slow and gradual, typically 6-12 weeks to reach optimal dose
• NICE NG87 specifies strict monitoring requirements for safety
• Shared care agreements allow GPs to manage established prescriptions
• Side effects usually resolve within 2-4 weeks as your body adapts

References

• National Institute for Health and Care Excellence (NICE). NG87: Attention deficit hyperactivity disorder: diagnosis and management. 2018.
• Banaschewski, T., Becker, K., Döpfner, M., Holtmann, M., & Rösler, M. (2017). Attention-deficit/hyperactivity disorder. The Lancet, 388(10064), 2937–2952.
• Cortese, S., Adley, E., Kuntsi, J., Sobanski, E., Tatlow-Golden, M., & European ADHD Guidelines Group (EAGG). (2020). European guidelines for the diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents: ADHD PartII: diagnosis and diagnosis–related interventions. European Child & Adolescent Psychiatry, 29(3), 459–488.
• UK Medicines and Healthcare products Regulatory Agency (MHRA). Approved medications for ADHD. 2026.